Because it is commonly accepted that AT2R and AT1R work in a contradictory manner [11,12], we hypothesized that AT2R agonism suppresses the proliferation activity in prostate cancer cells and down-regulates AR, similar to ARBs. Here, AR is linked to prostate carcinoma.